Literature DB >> 1635838

The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy.

I Danko1, V Chapman, J A Wolff.   

Abstract

The mdx mouse has been used for the development of cellular and gene therapies for Duchenne muscular dystrophy. The relatively frequent occurrence of dystrophin-positive muscle cells called revertants has hampered these efforts by interfering with data interpretation. The mdx4cv and mdx5cv dystrophin mouse mutants have approximately 10-fold fewer revertants than the mdx mutant at both 2 and 6 mo. The mdx3cv dystrophin mouse mutant may be a useful model for some types of human dystrophin deficiencies in which the levels of dystrophin are low but not completely absent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1635838     DOI: 10.1203/00006450-199207000-00025

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  64 in total

1.  Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.

Authors:  Paul S Sharp; Hema Bye-a-Jee; Dominic J Wells
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

3.  Genetically selected cardiomyocytes from differentiating embronic stem cells form stable intracardiac grafts.

Authors:  M G Klug; M H Soonpaa; G Y Koh; L J Field
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

4.  The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment.

Authors:  Gerlinde Wernig; Viktor Janzen; Ralf Schäfer; Margit Zweyer; Ulrich Knauf; Oliver Hoegemeier; Rustam R Mundegar; Stefan Garbe; Sebastian Stier; Thomas Franz; Marius Wernig; Anton Wernig
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-05       Impact factor: 11.205

5.  Removing the immune response from muscular dystrophy research.

Authors:  Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

6.  Building immune tolerance through DNA vaccination.

Authors:  Robin J Parks; Emanuela Gussoni
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-06       Impact factor: 11.205

7.  Flow Cytometry and Transplantation-Based Quantitative Assays for Satellite Cell Self-Renewal and Differentiation.

Authors:  Robert W Arpke; Michael Kyba
Journal:  Methods Mol Biol       Date:  2016

8.  Full-length dystrophin reconstitution with adeno-associated viral vectors.

Authors:  William Lostal; Kasun Kodippili; Yongping Yue; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

9.  Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein.

Authors:  Dejia Li; Yongping Yue; Dongsheng Duan
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

10.  Myotubularin-deficient myoblasts display increased apoptosis, delayed proliferation, and poor cell engraftment.

Authors:  Michael W Lawlor; Matthew S Alexander; Marissa G Viola; Hui Meng; Romain Joubert; Vandana Gupta; Norio Motohashi; Richard A Manfready; Cynthia P Hsu; Ping Huang; Anna Buj-Bello; Louis M Kunkel; Alan H Beggs; Emanuela Gussoni
Journal:  Am J Pathol       Date:  2012-07-27       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.